Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on July 31, 2012. The report discloses a significant corporate event: the signing of a three-year pharmaceutical supply agreement with Express Scripts, effective October 1, 2012.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. Instead, it outlines the projected financial impact of the new contract:
- Contract Value: Approximately $18.5 billion in annual pharmaceutical supply.
- Revenue Impact: Expected to contribute approximately 23% of the Registrant's total revenues.
- Earnings Impact: Expected to contribute approximately 3% of earnings per share.
Material Changes
The primary material change is the execution of the long-term supply agreement with Express Scripts. The filing explicitly states that this contract award has no impact on the company's expectations for fiscal 2012 or its preliminary expectations for fiscal 2013, which were previously disclosed on July 26, 2012.
Guidance, Outlook, and Risks
Management commentary indicates that the new agreement aligns with existing financial guidance. There are no new risks, contingencies, or unusual items disclosed in this specific filing beyond the standard execution of a major commercial contract. The company maintains its previously issued outlook for fiscal years 2012 and 2013.
Investor Verification Checklist
- Verify the effective date of the Express Scripts agreement (October 1, 2012).
- Confirm the projected revenue contribution (23%) and EPS contribution (3%) against total company forecasts.
- Review the July 26, 2012 news release to understand the baseline fiscal 2012 and 2013 expectations mentioned in this filing.
- Note that the filing refers to the company as AmerisourceBergen Corporation; verify current corporate name status (Cencora, Inc.).